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Here we report that miR-26b is involved in COX-2 overexpression in desferrioxamine (DFOM)-
treated carcinoma of nasopharyngeal epithelial (CNE) cells. The level of miR-26b in DFOM-treated
CNE cells is inversely proportional to the expression level of the COX-2 protein. Overexpression of
miR-26b in DFOM-treated CNE cells inhibits cell proliferation. A luciferase reporter gene experiment
suggests that the 30 untranslated region of COX-2 carries a binding site for miR-26b. Overexpression
of miR-26b marginally reduces the levels of COX-2 protein in DFOM-treated CNE cells. Moreover,
knockdown of COX-2 expression had a similar effect to overexpression of miR-26b. Taken together,
these results suggest that miR-26b regulates COX-2 expression in DFOM-treated cells.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are small non-coding RNA molecules of
18–24 nucleotides. MiRNAs play important roles in the control of
gene expression to regulate various biological processes, such as
development, cell differentiation, cell proliferation, and apoptosis.
MiRNAs regulate gene expression at the translational level by base
pairing to the 30-untranslated region (30-UTR) of target messenger
RNAs [1]. MiRNAs play a signiﬁcant role in cellular transformation
and carcinogenesis acting either as oncogenes or tumour suppres-
sors. Overexpressed miRNAs in caners, such as miR-17-92 cluster
and miR-191, may function as oncogenes and promote cancer
development by negatively regulating tumor suppressor genes
and genes that control cell proliferation or apoptosis. Underex-
pressed miRNAs in cancers, such as let-7, function as tumor sup-
pressor genes and may inhibit cancers by regulating oncogenes
and genes that control cell proliferation and apoptosis [2,3].
Cyclooxygenase-2 (COX-2) is an inducible enzyme that cata-
lyzes the conversion of arachidonic acid to prostaglandinschemical Societies. Published by E
inoma of nasopharygeal epi-
icroRNAs; miR-NC, miRNA
n-miR-NC, miRNA inhibitor
glyceraldehyde-3-phosphate(PGs) and other eicosanoids. COX-2 is undetectable in most nor-
mal tissues but is induced in response to hypoxia, inﬂammatory
cytokines, tumor promoters, growth factors, and other stressors
[4–6]. COX-2 is involved in tumor development and growth
through enhancement of tumor proliferation and angiogenesis
[7,8]. The expression of COX-2 could be regulated at various lev-
els. Firstly, the control of COX-2 transcription could be mediated
by various transcription factors, such as NF-jB [5,9], C/EBP
[10,11], NFAT [12], AP-1 [13], and PPAR [14]. Secondly, COX-2
expression could also be regulated at the post-transcriptional le-
vel through changes in its mRNA stability. AU-rich sequence ele-
ments in the 2.3 kb 30-UTR of COX-2 mRNA have been
demonstrated to regulate COX-2 expression at the levels of
mRNA stability and translation [15]. Finally, it was reported that
miR-199a and miR-101a are implicated in COX-2 regulation
[16,17].
Nasopharyngeal carcinoma ranks among the top 10 cancers in
southern China. In our previous study, we found that the expres-
sion of miR-26b was more than 38 fold downregulated in carci-
noma of nasopharyngeal epithelia (CNE) cells under DFOM-
induced hypoxia condition [18]. In this study, we found a binding
site for miR-26b in the 30-UTR of COX-2 mRNA with bioinformatics
approach. We experimentally assessed whether COX-2 could be
regulated by miR-26b and whether overexpression of COX-2 could
be the result of downregulated expression of miR-26b in CNE cells
under DFOM-induced hypoxia condition.lsevier B.V. All rights reserved.
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2.1. Cell culture and DFOM treatment
Cell lines CNE and 293 were obtained from the Chinese Acad-
emy of Science cell bank (Shanghai, china). The cells were main-
tained in Dulbecco’s Modiﬁed Eagle’s Medium containing 10%
FBS at 37 C with 5% CO2. DFOM treatment was carried out with
DFOM (Sigma) at a ﬁnal concentration of 130 lM, and cells without
DFOM treatment were used as a control [18].
2.2. Transfection
MiRNA-26b, miRNA negative control (miR-NC), miR-26b inhib-
itor (In-miR-26b), miRNA inhibitor negative control (In-miR-NC),
COX-2 siRNA [19] and control siRNA were synthesized and puriﬁed
by Shanghai GenePharma Co. Transfection was performed with
lipofectamine 2000 Reagent (Invitrogen), following the manufac-
ture’s protocol. Brieﬂy, cells were seeded into 96 or 24 well plates
one day prior to transfection. When the cells reached 50–70% con-
ﬂuence, miRNAs or siRNAs were transfected into the cells at differ-
ent ﬁnal concentrations.
2.3. RNA isolation and real-time RT-PCR
Total RNA was isolated with TRIzol Reagent (Invitrogen) and
miRNA extraction was performed with the mirVana miRNA Isola-
tion Kit (Ambion), according to the manufacturer’s protocol. MiR-
26b and COX-2 mRNA levels were analyzed by real-time PCR using
a SYBR premix kit (TaKaRa). For the detection of mature miRNAs,
small RNA extracted from cells was reverse transcribed to cDNA
using M-MLV reverse transcriptase (Promega) and the primer:
50-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGA-
CACCTAT-30, which can fold into a stem-loop structure. The cDNA
was used for the ampliﬁcation of mature miR-26b using primers
forward 50-CGCCGCTTCAAGTAATTCAGGAT-30 and reverse 50-
GTGCAGGGTCCGAGGT-30. The expression of miR-26b was normal-
ized against U6 snRNA levels, and the U6 primers were forward 50-
CTTCGGCAGCACATATACT-30 and reverse 50-AAAATATGGAACACTT-
CACG-30. For the detection of COX-2 mRNA, total RNA was reverse
transcribed to cDNA primed by oligo (dT) using M-MLV reverse
transcriptase and subsequently by PCR using primers forward 50-
CCTGTGCCTGATGATTGC-30, reverse 50-CTGATGCGTGAAGTGCTG-
30. An endogenous control gene, glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), was ampliﬁed using primers forward
50-AATCCCATCACCATCTTCCAGG-30, reverse 50-GAGTGGGTGTCGCT
GTTGAAGT-30.
2.4. Bioinformatics method, 30-UTR datasets and microRNA Datasets
MiRNA target site prediction for COX-2 was performed using
Targetscan Release 4.0 (http://www.targetscan.org). The 30-UTR se-
quences of COX-2 were retrieved using Ensembl Data base (http://
www.ensembl.org). Human miRNA sequences of the miR-26b reg-
istry were downloaded from the miRBase website (http://
www.mirbase.org).
2.5. Vector construction
To construct the luciferase report vector, COX-2 30-UTR and its
ﬂanking sequence was PCR-ampliﬁed using primers forward 50-
CGGGGTACCGAGTCATACTTGTGAAG-30 and reverse 50-GCACTC-
GAGC CTGTTTTTGTTTGATG-30. The ampliﬁed fragment was cloned
into vector PGL3 (Promega). Similarly, a mutated COX-2 30-UTR
fragment, in which the miR-26b binding site was mutated, wasPCR-ampliﬁed using primers forward 50-GTGGTTTCAACTTATATTA-
TAAGAACG-30 and reverse 50-GACGAAAAGACGTCAAAACTCATTT-
30. The PCR product was cloned into vector PGL3.
2.6. Luciferase activity assay
The 293 cells were transfected with either PGL3-empty
(500 ng), PGL3/COX-2 30-UTR (500 ng), PGL3/COX-2 30-UTR mutant
(500 ng), pRL-TK (50 ng, Promega), miR-26b (20 nM), miR-NC
(20 nM), In-miR-26b (20 nM), or In-miR-NC (20 nM). Cell lysate
was collected and assayed 48 h after transfection. Fireﬂy and Renil-
la luciferase activities were measured using a Dual Luciferase Re-
porter Assay System (Promega).
2.7. Western blotting
Cell lysate was subjected to SDS–PAGE and transferred to a
nitrocellulose membrane. Protein expression was analyzed by
Western blotting with primary antibodies against COX-2 (Santa
Cruz, sc-70879) and then incubated with a secondary antibody.
After washing, the proteins were visualized with an ECL kit
(Amersham).
2.8. CCK-8 assay
CNE cells were seeded into 96-well plates at 3000 cells per well
in 100 ll cell culture medium and incubated at 37 C for about
24 h. DFOM treatment was carried out with DFOM (Sigma) at a ﬁ-
nal concentration of 130 lM. When the cells reached 50–70% con-
ﬂuence, miRNAs or siRNAs were transfected. After incubation for
72 h, the cells were incubated with CCK-8 solution (10 ll/well)
for another 2–3 h. Viability determination was based on the bio-
conversion of the tetrazolium compound by intracellular dehydro-
genase into formazan, as determined by absorbance at 450 nm
using an Inﬁnite 2000 plate reader (TECAN).
2.9. Colony formation assay
After transfection with 200 nM of miR-26b, or 200 nM of miR-
NC, DFOM-treated cells were trypsinized, counted, and seeded
for a colony formation assay in 12-well plates at 100 cells per well.
During colony growth, the culture medium was replaced every
3 days. The number of colonies was counted on the ﬁfth day after
seeding. Colony formation rate was calculated using the equation:
colony formation rate = (number of colonies/number of seeded
cells)  100%. Each treatment was carried out in triplicate.
3. Results
3.1. The expressions of miR-26b and COX-2 protein are inversely
proportional in DFOM-treated CNE cells
Fig. 1A shows that the expression of miR-26b was downregu-
lated in DFOM-treated CNE cells. We found that CNE cells ex-
pressed different levels of COX-2 protein and mRNA before and
after DFOM-treatment. As shown in Fig. 1B, both the expression
of COX-2 protein and mRNA were upregulated in DFOM-treated
CNE cells compared with control cells. In DFOM-treated cells, high
levels of COX-2 protein were associated with moderate mRNA lev-
els. In control cells, low levels of COX-2 protein were associated
with low mRNA levels. It should be pointed out that nasopharyneal
carcinoma cells show variable cell speciﬁc results regarding the
correlation between levels of COX-2 mRNA with COX-2 protein.
Chan et al. reported that three NPC cell lines (HK-1, Hone-1 and
CNE-2) expressed the COX-2 mRNA, and only HK-1 expressed
Fig. 1. The expression of miR-26b and COX-2 protein in CNE cells with or without DFOM treatment. (A) Real-time PCR analysis of miR-26b in CNE cells with or without DFOM
induction for 48 h. miR-26b expression was normalized against U6 snRNA levels. (B) COX-2 protein and mRNA levels were analyzed in CNE cells with or without DFOM
induction for 48 h by western blot and real-time PCR, respectively. COX-2 protein expression was normalized against GAPDH protein levels and COX-2 mRNA expression was
normalized against GAPDHmRNA levels. (C) Effect of endogenous miR-26b on COX-2. CNE cells were transfected (50 nM ﬁnal concentration) with in-miR-26b and in-miR-NC.
Cell lysate was collected and assayed 48 h after transfection. COX-2 protein expression was analyzed by western blot. COX-2 protein expression was normalized against
GAPDH protein levels. Data are represented the mean ± S.D. of three independent experiments. *P < 0.05, **P < 0.01.
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on the expression of COX-2 protein in CNE cells without DFOM
treatment. When in-miR-26b was transfected into CNE cells, the
expression of COX-2 protein increased, as shown in Fig. 1C.
3.2. Overexpression of miR-26b inhibits cellular proliferation in DFOM-
treated CNE cells
To investigate the effect of miR-26b on cellular proliferation,
miR-26b was transfected into DFOM-treated CNE cells. Fig. 2A
shows that the metabolism of cells was reduced with miR-26b
overexpressed. To further test the anti-proliferative effect of
miR-26b on the growth of DFOM-treated CNE cells, miR-26b
was transfected into cells separately at ﬁnal concentrations of
10–1000 nM. Fig. 2B shows that cellular proliferation gradually
decreased as the content of miR-26b increased. Moreover, acolony formation assay showed that the colony number of
DFOM-treated CNE cells transfected with miR-26b was signiﬁ-
cantly lower than those transfected with miR-NC (Fig. 2C). We
investigated the effect of DFOM treatment on proliferation of
CNE cells. The cell proliferation has no signiﬁcant difference be-
tween cells with and without DFOM treatment at current concen-
tration of 130 lM (data not shown).
COX-2 has been widely reported to be involved in tumor devel-
opment and growth by enhancing the proliferation of the tumor.
To investigate the role of COX-2 in DFOM-treated cellular prolifer-
ation, a small interfering RNA (siRNA) that targeted COX-2 [19]
was transfected into DFOM-treated CNE cells. After transfection
for 72 h, a CCK-8 assay showed that proliferation was reduced with
COX-2 siRNA transfection (Fig. 2D). Fig. 2E shows that the expres-
sions of both COX-2 mRNA and protein were signiﬁcant reduced
with COX-2 siRNA transfection.
Fig. 2. Overexpression of miR-26b inhibits cellular proliferation in DFOM-treated CNE cells. Cell growth activity was measured by a CCK-8 assay. (A) DFOM-treated CNE cells
were transfected with miR-26b or miR-NC at a ﬁnal concentration of 50 nM and CCK-8 assay was performed 72 h after transfection. Values are mean ± S.D. of ﬁve
independent experiments. (B) Gradually increased quantities of miR-26b from 10 to 1000 nM were transfected into DFOM-treated CNE cells and dose-dependent anti-
proliferative effects were detected with a CCK-8 assay. Values are mean ± S.D. of ﬁve independent experiments. (C) The effect of miR-26b on cell proliferation was evaluated
by a colony formation assay. DFOM-treated CNE cells were transfected with miR-26b or miR-NC at a ﬁnal concentration of 200 nM and seeded in 12-well plates. The number
of colonies was counted on the ﬁfth day after seeding. Colony formation rate was calculated and shown. (D) DFOM-treated CNE cells were transfected with COX-2 siRNA or
control siRNA at a ﬁnal concentration of 50 nM and CCK-8 assay was performed 72 h after transfection. Values are mean ± S.D. of ﬁve independent experiments. (E) CNE cells
were transfected (50 nM ﬁnal concentration) with COX-2 siRNA and control siRNA. COX-2 mRNA and protein were analyzed by western blotting and real-time PCR 48 h after
transfection. COX-2 protein and COX-2 mRNA were normalized against GAPDH protein and GAPDH mRNA, respectively. Data are represented the mean ± S.D. of three
independent experiments. **P < 0.01.
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To investigate whether miRNA is involved in the regulation of
COX-2 expression, we analyzed miRNA binding sites in the 30-
UTR of COX-2 and its cognate miRNAs using a bioinformatics ap-
proach. With the help of the TargetScan Release 4.0 database, wefound a binding site for miR-26b in the 30-UTR of COX-2 mRNA
(Fig. 3A).
To certify that miR-26b can bind to the predicted region and
cause translational repression, we performed a luciferase reporter
gene assay in 293 cell lines. The 30-UTR of COX-2 mRNA containing
the putative miR-26b binding site was cloned into a luciferase
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taining mutated COX-2 30-UTR as shown in Fig. 3A. Cell treatments
were shown as Fig. 3B. Fig. 3C shows that the luciferase activity
signiﬁcantly decreased after co-transfection with PGL3/COX-2 30-
UTR and miR-26b, compared with control cells co-transfected with
PGL3/COX-2 30-UTR and miR-NC. Transfection with In-miR-26b in-
creased the luciferase activity. Luciferase activity did not change
when the cells were transfected with miR-NC or In-miR-NC. In con-
trast, we did not observe variations of the luciferase activity in cells
co-transfection with PGL3/COX-2 30-UTR mutant and miR-26b, in
comparison to cells co-transfected with PGL3/COX-2 30-UTR mu-
tant and miR-NC or cells transfected only with PGL3/COX-2 30-
UTR mutant. Fig. 3D shows that the luciferase activity decreased
after transfection with PGL3/COX-2 30-UTR in DFOM-untreated
CNE cells, comparing to the CNE cells with DFOM treatment. The
results suggested that miR-26b could speciﬁcally bind to the 30-
UTR of COX-2 mRNA and repress COX-2 expression.
The effect of miR-26b transfection on COX-2 expression was di-
rectly evaluated in DFOM-treated CNE cell lines. The experiment
used three different negative controls (cells treated only with lipo-
fectamine 2000 and cells transfected with miR-NC or control siR-
NA) and one positive control (cell transfected with COX-2 siRNA),
as shown in Fig. 4A. Fig. 4B shows that the expression of COX-2
protein was reduced in DFOM-treated CNE cells transfected with
miR-26b comparing with the controls. The similar result was ob-
tained in the cells transfected with COX-2 siRNA. The results sup-
port the hypothesis that COX-2 mRNA is a direct target for miR-
26b.
4. Discussion
To date, many studies on tumorigenesis have focused on alter-
ations of miRNAs in cancer and the identiﬁcation of biological
targets of miRNA in cancer-associated genes. It was suggested thatFig. 3. miR-26b binds COX-2 mRNA and inhibits its translation. (A) A potential target
potential target sequence. (B) Cell treatments. (C) A luciferase assay was carried out on 2
Fireﬂy luciferase activity was evaluated 48 h after cotransfection with PGL3-empty/Cox-2
26b (20 nM), In-miR-NC (20 nM) as indicated. (D) Fireﬂy luciferase activity in DFOM-trea
Cox-2 30-UTR mutant (500 ng) respectively. Data were normalized against Renilla lucif
represented the mean ± S.D. of three independent experiments. *P < 0.05, **P < 0.01.miRNAs can act as tumor suppressors or oncogenes to regulate the
key pathways involved in cellular growth and death control [21].
Other studies identiﬁed a variety of hypoxia-regulated miRNAs,
providing a link between a stress factor and gene expression con-
trol. It was found that the expression of miR-210 was increased
upon exposure to hypoxia and inhibited the gene expression of
Ephrin-A3 in endothelial cells [22].
Hypoxia is observed in nearly all solid tumors and often in sur-
rounding areas of necrosis. When faced with low oxygen supply,
the cells orchestrate a coordinated response with the intent of
restoring oxygen homeostasis. The expressions of many genes
change during hypoxia, including COX-2. For example, in RCE cells,
COX-2 protein levels are markedly increased in response to hypox-
ia, and the increase was time-dependent and correlated with
increasing levels of COX-2 mRNA [23]. COX-2 expression and activ-
ity are induced by hypoxia in prostate cancer and human umbilical
vein endothelial cells [5,24]. COX-2 overexpression under hypoxia
is regulated by NF-jB and HIF-1a factor [5,25,26]. In our previous
study, we found that miR-26b expression was sharply downregu-
lated in DFOM-treated cells. DFOM, an iron chelator, has the ability
of hypoxia mimetics to upregulate several inﬂammatory mediators
[27,28]. It was reported that the expression of COX-2 protein accu-
mulation is increased with DFOM treatment in a dose-dependent
manner in the cancer cell lines [26]. In this study, we examine
whether miR-26b is involved in the COX-2 expression in DFOM-in-
duced hypoxia condition. We conﬁrmed that miR-26b expression
decreased in DFOM-treated CNE cells, and found that the expres-
sions of miR-26b and COX-2 protein are inversely correlated in
DFOM-treated CNE cells.
MiRNA regulation of gene expression plays a role in develop-
ment, differentiation, proliferation, and apoptosis. For example,
miR-34a inhibition of silent information regulator 1 could regulate
cell apoptosis [29]. Up to now, there was no evidence about the
function of miR-26b in cell proliferation and apoptosis. Whenfor miR-26b was found in the 30-UTR of COX-2. Mutations were generated in the
93 cells using PGL3/COX-2 30-UTR and PGL3/ COX-2 30-UTR mutant reporter vectors.
30-UTR/Cox-2 30-UTR mutant (500 ng), miR-26b (20 nM), miR-NC (20 nM), In-miR-
ted CNE cells was evaluated 48 h after transfection with PGL3-empty/Cox-2 30-UTR/
erase activity (all samples were cotransfected with 50 ng pRL-TK vector). Data are
Fig. 4. miR-26b regulates COX-2 expression in DFOM-treated CNE cells. DFOM-
treated CNE cells were transfected (50 nM ﬁnal concentration) with COX-2 siRNA,
control siRNA, miR-26b and miR-NC. (A) Cell treatments. (B) COX-2 protein, COX-2
mRNA and miR-26b were analyzed in DFOM-treated CNE cells by western blotting
and real-time PCR 48 h after transfection. COX-2 protein, COX-2 mRNA and miR-
26b expression were normalized against GAPDH protein, GAPDH mRNA and U6
snRNA levels, respectively. All data are represented the mean ± S.D. of three
independent experiments. **P < 0.01.
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proliferation decreased, indicating that miR-26b could regulate cell
growth by interfering with the expression of proteins linked to cel-
lular proliferation or apoptosis. At the same time, COX-2 protein
was upregulated in DFOM-treated cells. It is well established that
COX-2 and its resultant prostaglandins increase tumor cell prolifer-
ation, resistance to apoptosis, and angiogenesis [7,8]. Our results
showed that knockdown of COX-2 could decrease the proliferation
of DFOM-treated cells, and the similar result was obtained in
DFOM-treated cells transfected with miR-26b. However, it was re-
ported that DFOM treatment decreased the cyclin D1 protein
expression via an ubiquitin-independed pathway through the pro-
teasome. The degradation of cyclin D1 protein could results in G1/S
arrest and inhibits cell growth [30]. In our experiments, it was
found that the CNE cell proliferation has no signiﬁcant difference
between cells with and without DFOM treatment at the concentra-
tion of 130 lM. This may be caused by an overall effect of many
genes regulation from DFOM-treatment.
Computational algorithms showed that the 30-UTR of COX-2
mRNA contained a binding site for miR-26b. To conﬁrm targeting
of COX-2 by miR-26b, we integrated a fragment of the COX-2
mRNA 30-UTR containing the target sequence, or a fragment whose
target site was mutated, into a luciferase reporter vector. Lucifer-
ase activity was signiﬁcantly repressed in the construct harboringthe miR-26b target sequence compared with cells harboring the
mutated control vector. These data indicated miR-26b could di-
rectly interact with COX-2 mRNA and repress COX-2 protein
expression. The mechanisms of the function of miRNA in repress-
ing protein synthesis are still poorly understood. It was pointed
out that animal miRNAs can induce signiﬁcant degradation of
mRNA targets [31]. Giraldez et al. reported that miR-430 facilitates
the deadenylation and clearance of maternal mRNAs during early
embryogenesis [32]. In our study, both the levels of COX-2 mRNA
and protein decreased after miR-26b transfection, as shown in
Fig. 4. A possible explanation of this phenomenon might be that
miR-26b downregulates COX-2 expression by mRNA cleavage.
In summary, the expression levels of miR-26b and COX-2 pro-
tein were inversely correlated in DFOM-treated CNE cells. The re-
sults presented here suggest that miR-26b directly silences COX-
2 in DFOM-treated CNE cells and regulates COX-2 expression.Acknowledgments
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